Skip to main content
. Author manuscript; available in PMC: 2022 Feb 1.
Published in final edited form as: Nano Today. 2020 Dec 14;36:101045. doi: 10.1016/j.nantod.2020.101045

Figure 5. Treatment with MHA112-Taxol prolonged survival of mice in a metastatic breast cancer model.

Figure 5.

(A) Fluorescence micrograph of 4T1 tumor in the liver revealed overlapping of vWF+ blood endothelial cells (red) with HEVs (green). Scale bar: 200μm. (B) Survival curve of metastatic 4T1 breast tumor mouse model showed significantly longer survival of MHA112-Taxol-treated mice (n=5, MST=57) than the untreated control, free Taxol and IgM isotype-Taxol-treated groups (n=5, MST=33, 37, 36, respectively). Red triangles indicated the injection timepoints. (C) Representative photographs of 4T1 tumors in mouse livers showed significantly smaller size in the MHA112-Taxol group (n=5) than the other three groups (n=5). (D) Fluorescence micrographs of metastatic tumor lesions showed lower tumor cell proliferation (Ki67) and ECM accumulation (collagen I), and less expanded vasculature (CD31) in the MHA112-Taxol group than the other groups. Scale bar: 100μm. Quantification data from two independent experiments with five mice/group (n=5) are summarized in bar chart. *p < 0.05, **p < 0.01, ***p < 0.001.